Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.

Noblejas-López MDM, Nieto-Jiménez C, Morcillo García S, Pérez-Peña J, Nuncia-Cantarero M, Andrés-Pretel F, Galán-Moya EM, Amir E, Pandiella A, Győrffy B, Ocana A.

Oncoimmunology. 2019 Jul 3;8(10):e1629780. doi: 10.1080/2162402X.2019.1629780. eCollection 2019.

PMID:
31646075
2.

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Noblejas-López MDM, Nieto-Jimenez C, Burgos M, Gómez-Juárez M, Montero JC, Esparís-Ogando A, Pandiella A, Galán-Moya EM, Ocaña A.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383. doi: 10.1186/s13046-019-1387-5.

3.

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy.

Niza E, Nieto-Jiménez C, Noblejas-López MDM, Bravo I, Castro-Osma JA, Cruz-Martínez F, Buchaca MMS, Posadas I, Canales-Vázquez J, Lara-Sanchez A, Hermida-Merino D, Solano E, Ocaña A, Alonso-Moreno C.

Nanomaterials (Basel). 2019 Aug 27;9(9). pii: E1208. doi: 10.3390/nano9091208.

4.

Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models.

Corrales Sánchez V, Nieto-Jiménez C, Castro-Osma JA, de Andrés F, Pacheco-Liñán PJ, Bravo I, Rodríguez Fariñas N, Niza E, Domínguez-Jurado E, Lara-Sánchez A, Ríos Á, Gómez Juárez M, Montero JC, Pandiella A, Shafir A, Alonso-Moreno C, Ocaña A.

ACS Omega. 2019 Aug 1;4(8):13005-13014. doi: 10.1021/acsomega.9b00296. eCollection 2019 Aug 20.

5.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

6.

Mapping Bromodomains in breast cancer and association with clinical outcome.

Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, Győrffy B, Ocana A.

Sci Rep. 2019 Apr 5;9(1):5734. doi: 10.1038/s41598-019-41934-3.

7.

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Noblejas-López MDM, Morcillo-García S, Nieto-Jiménez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A.

PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.

8.

Impact of Hypothermic Stress During Special Operations Training of Chilean Military Forces.

Nieto Jimenez C, Cajigal Vargas J, Triantafilo Vladilo VS, Naranjo Orellana J.

Mil Med. 2018 Jul 1;183(7-8):e193-e199. doi: 10.1093/milmed/usx131.

PMID:
29425375
9.

BET inhibitors as novel therapeutic agents in breast cancer.

Ocaña A, Nieto-Jiménez C, Pandiella A.

Oncotarget. 2017 Aug 1;8(41):71285-71291. doi: 10.18632/oncotarget.19744. eCollection 2017 Sep 19. Review.

10.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

11.

Neutrophils in cancer: prognostic role and therapeutic strategies.

Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ.

Mol Cancer. 2017 Aug 15;16(1):137. doi: 10.1186/s12943-017-0707-7. Review.

12.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

13.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

14.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Nieto-Jiménez C, Alcaraz-Sanabria A, Páez R, Pérez-Peña J, Corrales-Sánchez V, Pandiella A, Ocaña A.

Oncotarget. 2016 Jul 28;8(38):62834-62841. doi: 10.18632/oncotarget.10886. eCollection 2017 Sep 8.

15.

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.

Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Nieto-Jiménez C, Templeton AJ, Seruga B, Pandiella A, Amir E.

Oncotarget. 2016 Apr 19;7(16):22865-72. doi: 10.18632/oncotarget.8118.

Supplemental Content

Loading ...
Support Center